AI x Oncology & Gene Editing

Hosted by Willy Braun, Maria & Benjamin Belot

Approval Required

Your registration is subject to approval by the host.

Welcome! To join the event, please register below.

You will be asked to verify token ownership with your wallet.

About Event

AI meets DNA: Oncology & Gene Editing

Oncology and gene editing are no longer emerging fields, they are at an inflection point.

AI-driven single-cell analysis, CRISPR variants beyond Cas9, and programmable recombinases are moving from proof-of-concept to clinical and industrial application. These technologies are not only redefining therapeutic paradigms in cancer, but also expanding into agriculture and synthetic biology.

This evening convenes founders and investors at the frontier, to examine how these innovations translate from the lab bench into platforms and products that can reshape industries:

7:00 – 7:45 | Panel 1 — AI × Oncology
Spotlight Medical and OneBioscience are turning cutting-edge AI into precision tools against cancer. (Final line-up in progress)

8:00 – 8:45 | Panel 2 — Gene Editing: Human vs Plant
EPICS Biotechnology and BrinkTx push the limits of CRISPR and beyond, from miniature Cas systems to next-gen recombinases. (Final line-up in progress)

9:00 – 9:30 | Networking
Continue the conversation over drinks and connect with founders, researchers, and investors.

📅 When: Thursday, October 30, 2025
📍 Where: Paris, city center
🔥 Spots are limited

Come for the science, stay for the ideas, and connect with the people shaping tomorrow’s biotech breakthroughs.

Organised by Galion.exe, Kurma, and Alven, as part of BioWeek Paris.

___

Alven is an independent early-stage venture capital firm with a successful track record of 5 successive funds backing more than 160 startups over 22 years. As of 2022 Alven has over €2b in funds under management.

EPICS Biotechnology is a synthetic biology company developing plant-derived biopesticides and biostimulants to support a more sustainable and cost-effective crop input market

Galion.exe is a seed-stage venture capital fund investing across Europe and the US, focused on AI infrastructure, AI-powered SaaS, and health technologies. Its portfolio includes companies such as .omics, Alpic, Conception, Contrast, EPICS Biotechnology, Harmattan, Jimini, OneBioscience, Oria Bioscience, PriorLabs, Raidium, and Vaire, reshaping the future of science and technology.

Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).

One Biosciences is a precision oncology company that transforms cancer diagnosis through AI-powered single-cell technologies.

Hosted By

10 Going